30
Participants
Start Date
April 5, 2017
Primary Completion Date
July 2, 2019
Study Completion Date
July 2, 2019
Dolutegravir 50 mg
Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B\*5701 allele screening assessment.
Centro Hospitalar de Lisboa Central Hospital Curry Cabral, Lisbon
Centro Hospitalar de Lisboa Ocidental Hospital de Egas Moniz, Lisbon
Centro Hospitalar Lisboa Norte Hospital de Santa Maria, Lisbon
Hospital Beatriz Ângelo Loures, Lisbon
Hospital Garcia de Orta, Lisbon
Hospital Professor Doutor Fernando Fonseca Amadora, Lisbon
Lead Sponsor
Blueclinical, Ltd.
OTHER